BHV-7000 Open-Label Extension Bipolar Mania Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

April 25, 2025

Study Completion Date

April 25, 2025

Conditions
Bipolar Disorder
Interventions
DRUG

BHV-7000

BHV-7000 75 mg taken once daily

Trial Locations (32)

10329

RBA, Staten Island

20877

CBH Health, Gaithersburg

30030

CenExel iResearch, LLC, Decatur

30331

Atlanta Center for Medical Research, Atlanta

31405

CenExel iResearch, LLC, Savannah

33016

Floridian Neuroscience Institute, Miami Lakes

Segal Trials - Miami Lakes Medical Research-Inpatient & Early Phase Site, Miami Lakes

33021

Segal Trials - Larkin Behavioral Health Services-Inpatient & Early Phase Site, Hollywood

33024

Cenexel - RCA, Hollywood

33126

LCC Medical Research Inst, Miami

33407

Neuroscience Research Institute, West Palm Beach

39232

Precise Clinical Research, Flowood

44720

NBCR, North Canton

45417

Midwest Clinical Research Center, Dayton

60640

Uptown Research Institute, Chicago

60641

Pillar Clinical Research, Chicago

63141

Arch Clinical Trials, St Louis

72211

WIRG, Little Rock

72712

Pillar Clinical Research, LLC, Bentonville

72758

WRN, Rogers

75080

Pillar Clinical Research, LLC, Richardson

75115

InSite Clinical Research, LLC, DeSoto

78754

Community Clinical Research, Inc., Austin

90230

ProScience Research Group, Culver City

90504

Cenexel CNS, Torrance

90706

CIT LA, Bellflower

91945

Synergy San Diego, Lemon Grove

92506

CIT IE, Riverside

92805

Advanced Research Center, Inc., Anaheim

92845

Cenexel CNS, Garden Grove

92868

NRC Research Institute, Orange

08053

Hassman Research Institute, Marlton

Sponsors
All Listed Sponsors
lead

Biohaven Therapeutics Ltd.

INDUSTRY

NCT06423794 - BHV-7000 Open-Label Extension Bipolar Mania Study | Biotech Hunter | Biotech Hunter